|
Signal Transduction
Citations 141-150 of 1930 total displayed.
|
Past content
(since May 2000):
|
Diverging signaling events control the pathway of GPVI down-regulation in vivo
- Tamer Rabie, David Varga-Szabo, Markus Bender, Rastislav Pozgaj, Francois Lanza, Takashi Saito, Stephen P. Watson, and Bernhard Nieswandt
Blood 2007; 110: 529-535.
[Abstract]
[Full text]
[PDF]
Group V secretory PLA2 regulates TLR2-dependent eicosanoid generation in mouse mast cells through amplification of ERK and cPLA2 activation
- Eriya Kikawada, Joseph V. Bonventre, and Jonathan P. Arm
Blood 2007; 110: 561-567.
[Abstract]
[Full text]
[PDF]
A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature
- Sarah Cooley, Feng Xiao, Michelle Pitt, Michelle Gleason, Valarie McCullar, Tracy L. Bergemann, Karina L. McQueen, Lisbeth A. Guethlein, Peter Parham, and Jeffrey S. Miller
Blood 2007; 110: 578-586.
[Abstract]
[Full text]
[PDF]
A novel negative regulatory function of the phosphoprotein associated with glycosphingolipid-enriched microdomains: blocking Ras activation
- Michal Smida, Anita Posevitz-Fejfar, Vaclav Horejsi, Burkhart Schraven, and Jonathan A. Lindquist
Blood 2007; 110: 596-625.
[Abstract]
[Full text]
[PDF]
Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis
- Cristina Cerboni, Alessandra Zingoni, Marco Cippitelli, Mario Piccoli, Luigi Frati, and Angela Santoni
Blood 2007; 110: 606-615.
[Abstract]
[Full text]
[PDF]
Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells
- Lori Rink, Artur Slupianek, Tomasz Stoklosa, Margaret Nieborowska-Skorska, Katarzyna Urbanska, Ilona Seferynska, Krzysztof Reiss, and Tomasz Skorski
Blood 2007; 110: 651-660.
[Abstract]
[Full text]
[PDF]
Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells
- Rudin Kondo, Karoline V. Gleixner, Matthias Mayerhofer, Anja Vales, Alexander Gruze, Puchit Samorapoompichit, Khaled Greish, Maria-Theresa Krauth, Karl J. Aichberger, Winfried F. Pickl, Harald Esterbauer, Christian Sillaber, Hiroshi Maeda, and Peter Valent
Blood 2007; 110: 661-669.
[Abstract]
[Full text]
[PDF]
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells
- Tanyel Kiziltepe, Teru Hideshima, Kenji Ishitsuka, Enrique M. Ocio, Noopur Raje, Laurence Catley, Chun-Qi Li, Laura J. Trudel, Hiroshi Yasui, Sonia Vallet, Jeffery L. Kutok, Dharminder Chauhan, Constantine S. Mitsiades, Joseph E. Saavedra, Gerald N. Wogan, Larry K. Keefer, Paul J. Shami, and Kenneth C. Anderson
Blood 2007; 110: 709-718.
[Abstract]
[Full text]
[PDF]
NF- B2 mutation targets TRAF1 to induce lymphomagenesis
- Baochun Zhang, Zhe Wang, Tai Li, Erdyni N. Tsitsikov, and Han-Fei Ding
Blood 2007; 110: 743-751.
[Abstract]
[Full text]
[PDF]
Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration
- Paul Proost, Anneleen Mortier, Tamara Loos, Jo Vandercappellen, Mieke Gouwy, Isabelle Ronsse, Evemie Schutyser, Willy Put, Marc Parmentier, Sofie Struyf, and Jo Van Damme
Blood 2007; 110: 37-44.
[Abstract]
[Full text]
[PDF]
|
|
